| Literature DB >> 31113394 |
Arie Passov1, Liisa Petäjä2, Marjut Pihlajoki3, Ulla-Stina Salminen4, Raili Suojaranta4, Antti Vento4, Sture Andersson3, Ville Pettilä5, Alexey Schramko2, Eero Pesonen2.
Abstract
BACKGROUND: Acute kidney injury (AKI) is common after heart surgery. Neutrophil gelatinase-associated lipocalin (NGAL) is produced in injured kidney. NGAL has been used as an early plasma biomarker for AKI in patients undergoing heart surgery. Neutrophils contain all isoforms (25-kDa, 45-kDa and 145-kDa) but the kidney produces almost exclusively the 25-kDa isoform of NGAL. We investigated first, whether there is association between NGAL and neutrophil activation, and second whether activated neutrophils are a significant source of circulating NGAL in plasma in patients undergoing cardiac surgery.Entities:
Keywords: Acute kidney injury; Biomarkers; Cardiac surgery-associated acute kidney injury; Neutrophil activation; Neutrophil gelatinase-associated lipocalin (NGAL)
Year: 2019 PMID: 31113394 PMCID: PMC6530061 DOI: 10.1186/s12882-019-1380-4
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Title: Flow chart of the study cohorts. ELISA – Enzyme-linked immunosorbent assay, AKI – Acute Kidney Injury
Kinetic cohort
| Patient characteristics and procedure data | |
|---|---|
| Male gender | 14 (48.3%) |
| Age (years) | 66.0 (60.5–72.5) |
| Pre-operative creatinine (μmol/L) | 76.0 (68.5–89.0) |
| Cardiopulmonary bypass time (min) | 101 (85–114) |
| Aortic cross-clamping time (min) | 70 (58–79) |
| Chronic Kidney Disease | 7 (24.1%) |
| NGAL (ng/ml) | |
| | 13.2 (11.3–16.7) |
| | 9.3 (8.0–12.7) |
| | 25.2 (17.2–32.3) |
| | 30.0 (17.8–41.3) |
| Lactoferrin (ng/ml) | |
| | 62 (48–132) |
| | 403 (311–541) |
| | 975 (598–1275) |
| | 1177 (653–1377) |
Data are median (interquartile range) or number (percentage). NGAL neutrophil gelatinase-associated lipocalin
FINNAKI cohort. Patient characteristics and procedure data
| ALL [ | NO-AKI | AKI | |
|---|---|---|---|
| Age (years) | 68 (60–75) | 67 (58–74) | 71 (64–78)** |
| Male gender | 221 (72.2) | 171 (77.4) | 50 (73.5) |
| Co-Morbidity | |||
| Insulin dependent diabetes mellitus | 25 (8.2%) | 16 (6.7%) | 9 (13%) |
| Noninsulin dependent diabetes mellitus | 55 (18.0%) | 41 (17.2%) | 14 (20%) |
| Hypertension | 196 (64.1%) | 146 (61.3%) | 50 (73.5%) |
| Chronic Kidney Disease | 40 (13.1%) | 24 (10.0%) | 16 (23.5%)** |
| Pre-operative LVEF less than 30% | 11 (3.6%) | 9 (3.8%) | 2 (2.9%) |
| Surgery | |||
| CABG only | 152 (49.7%) | 124 (52.1%) | 28 (41.2%) |
| Valve-only | 101 (33.0%) | 79 (33.2) | 22 (32.4%) |
| CABG and valve | 38 (12.4) | 24 (10.1%) | 14 (20.6%)* |
| Other cardiac surgery | 9 (2.9%) | 8 (3.4%) | 1 (1.5%) |
| Aortic rupture or dissection | 6 (2.0) | 3 (1.3%) | 3 (4.4%) |
| Off-pump surgery | 28 (9.2%) | 26 (10.9%) | 2 (2.9%)* |
| Cardiopulmonary bypass timea (min) | 103 (82–147) | 102 (81–146) | 104 (84–155)* |
| Aortic cross-clamping timea (min) | 72 (57–101) | 74 (57–100) | 70 (55–113) |
Data are median (interquartile range) or number (percentage). aonly patients undergoing on-pump surgery used in calculations. *p < 0.05, **p < 0.01, ***p < 0.001 for AKI vs NO-AKI
LVEF left ventricular ejection fraction, ICU intensive care unit, CABG coronary artery bypass grafting, AKI acute kidney injury
FINNAKI cohort. Laboratory analyses
| ALL [N = 306] | NO-AKI [N = 238 (77.8%)] | AKI [N = 68 (22.2%)] | |
|---|---|---|---|
| Pre-operative creatinine ( | 84 (72–97) | 84 (72–94) | 92 (75–109)** |
| Pre-operative NGAL (ng/ml) | 21.5 (17.8–28.1) | 21.0 (17.2–26.8) | 22.6 (20.0–31.7)* |
| Pre-operative LF (ng/ml) | 117 (72–189) | 116 (72–192) | 119 (70–167) |
| Pre-operative WBC count (10E9) | 6.8 (5.7–8.2) | 6.7 (5.6–8.1) | 7.2 (6.2–9.1)* |
| NGAL at admission to ICU (ng/ml) | 39.0 (28.6–52.6) | 37.9 (27.3–48.7) | 48.8 (35.4–61.7)*** |
| LF at admission to ICU (ng/ml) | 489 (338–651) | 471 (336–622) | 538 (362–856)* |
| WBC count at 1st postoperative day (10E9) | 9.5 (7.9–12.1) | 9.2 (7.8–11.8) | 10.8 (8.2–13.0)* |
Data are median (interquartile range) or number (percentage). WBC - white blood cell count
*p < 0.05, **p < 0.01, ***p < 0.001 for AKI vs NO-AKI. NGAL neutrophil gelatinase-associated lipocalin, LF lactoferrin, WBC white blood cell, ICU intensice care unit
Fig. 2Kinetic cohort. NGAL indexed to LF (NGAL/LF ratio). Data are median (dots) interquartile range (whiskers). NGAL – neutrophil gelatinase-associated lipocalin, LF – lactoferrin, T1 – before induction of anaesthesia, T2 – before aortic crossclamping, T3 – before aortic declamping, T4 – five minutes after reperfusion
Fig. 3FINNAKI cohort. The correlation of NGAL and LF. NGAL – neutrophil gelatinase-associated lipocalin, LF – lactoferrin
Fig. 4FINNAKI cohort. Representative Western blots of NGAL at admission to ICU. NGAL – neutrophil gelatinase-associated lipocalin, AKI – Acute Kidney Injury
Fig. 5FINNAKI cohort. Distribution of NGAL isomers in patients with AKI and without AKI. NGAL – neutrophil gelatinase-associated lipocalin, AKI – Acute Kidney Injury
FINNAKI cohort. Quantification of NGAL isomers by Western blotting at admission to ICU
| ALL ( | NO AKI ( | AKI ALL ( | AKI STAGE-1 ( | AKI STAGE 2 ( | AKI STAGE 3 ( | |
|---|---|---|---|---|---|---|
| Monomeric, 25-kDa (%) | 0.9 (0.3–3.0) | 0.7 (0.4–1.5) | 0.9 (0.2–5.0) | 1.5 (0.2–7.0) | 0.7 (0.2–2.6) | 1.0 (0.4–3.9) |
| Dimeric, 45-kDa (%) | 41.2 (33.3–53.1) | 45.4 (33.3–54.3) | 41.2 (33.2–51.3) | 41.1 (39.4–55.1) | 39.4 (33.1–49.0) | 41.2 (24.7–61.4) |
| Hetero-dimeric, 145-kDa (%) | 53.5 (44.0–64.9) | 51.2 (42.6–66.4) | 53.8 (47.6–63.5) | 52.4 (42.1–58.9) | 56.6 (48.1–66.2) | 58.2 (36.0–70.7) |
| NGAL at admission to ICU (ng/ml) | 51.2 (37.2–77.3) | 47.0 (35.3–79. 5) | 53.4 (38.2–63.8) | 57.0 (42.4–85.2) | 47.3 (20.5–55.2) | 54.0 (39.1–62.5) |
| AKI Risk-score | 0.24 (0.16–0.41) | 0.17 (0.10–0.30) | 0.32** (0.18–0.47) | 0.24 (0.20–0.43) | 0.37 (0.19–0.49) | 0.29 (0.18–0.52) |
Data are median (interquartile range).™
*p < 0.05, **p < 0.01, ***p < 0.001 for AKI vs NO-AKI. AKI acute kidney injury